A Bioequivalence Study Of AG-013736 Tablets Under Fed Conditions In Healthy Volunteers
A Bioequivalence Study Of AG-013736 Tablets Under Fed Conditions In Healthy Volunteers
The purpose is to show that 5 mg Form IV tablet of AG-013736 produces similar drug
 concentrations in plasma compared to 5 mg Form XLI tablet of AG-013736 after oral dosing
 under fed conditions.
To establish bioequivalence between Form IV and Form XLI of AG-013736 tablets
Inclusion Criteria:

 -  Healthy male and/or female subjects between the ages of 21 and 47 years, inclusive
 (Healthy is defined as no clinically relevant abnormalities identified by a detailed
 medical history, full physical examination, including blood pressure and pulse rate
 measurement, 12-lead electrocardiogram (ECG) and clinical laboratory tests)

 -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)

 -  An informed consent document signed and dated by the subject or a legally acceptable
 representative

 Exclusion Criteria:

 -  Evidence of significant disease of the blood, kidney, endocrine system, lungs,
 gastrointestinal, heart, liver, psychiatric, neurologic, or allergic (including drug
 allergies, but excluding season allergies)

 -  Use of tobacco- or nicotine- containing products (or a positive urine cotinine test).

 -  Pregnant or nursing females and females of childbearing potential including those with
 tubal ligation